Acapsular *Pasteurella multocida* B:2 Can Stimulate Protective Immunity against Pasteurellosis

JOHN D. BOYCE AND BEN ADLER*

Bacterial Pathogenesis Research Group, Department of Microbiology, School of Biomedical Sciences, Monash University, Victoria, 3800, Australia

Received 20 September 2000/Returned for modification 24 October 2000/Accepted 20 November 2000

We have previously shown that a *Pasteurella multocida cexA* mutant (PBA875) was impaired in capsule export and highly attenuated in virulence for mice (J. D. Boyce and B. Adler, Infect. Immun. 68:3463–3468, 2000). In this study we show that immunization with high, but not low, doses of PBA875 can confer significant protection against wild-type challenge. We have also constructed a genetically defined acapsular *P. multocida* strain (AL18) by inactivation of *bcbH*, a gene predicted to be involved in polysaccharide biosynthesis. AL18 failed to produce immunoreactive polysaccharide as determined by immunofluorescence and Western immunoblot. Immunization of mice with live AL18 conferred significant protection against wild-type challenge, while immunization with similar doses of either killed wild-type or killed AL18 failed to confer protection.

The gram-negative bacterium *Pasteurella multocida* is the etiological agent of hemorrhagic septicemia in cattle, fowl cholera in birds, and atrophic rhinitis in pigs (18). *P. multocida* strains can be separated into serogroups A, B, D, E, and F based on the antigenicity of their capsule (6, 26) and serotypes 1 to 16 based on lipopolysaccharide (LPS) antigens (12). The capsular serogroup is generally related to disease predilection, with hemorrhagic septicemia strains belonging to serogroup B or E (30) and the majority of fowl cholera strains belonging to serogroup A (7).

Hemorrhagic septicemia is endemic in most parts of tropical Asia, Africa, and India and causes high mortality in livestock (2). It is considered to be the most economically important disease of livestock in South East Asia and causes significant economic losses in India and Africa (2, 30). Cattle and buffalo are the most common hosts, but pigs, sheep, goats, deer, and camels are also susceptible to infection and disease (3, 9).

Vaccination with undefined, killed vaccines is practiced in areas where the disease is endemic and has reduced the incidence of disease, but the duration of immunity is short and significant outbreaks still occur (2, 30). Little is known about why vaccination procedures sometimes fail.

Current *P. multocida* vaccines contain either inactivated bacteria (bacterins) or live attenuated bacteria (10, 20, 30). Bacterins are inexpensive to produce but must be injected, often cause severe tissue reactions, and give very limited protection against heterologous serotypes (8, 25). Furthermore, it is not uncommon for groups vaccinated with these bacterins to suffer disease outbreaks (28). Immunization with live attenuated bacteria or bacterins derived from in vivo-grown cells elicits the production of antibodies which give protection against a range of serotypes (14, 25–27). This suggests that antigens expressed solely in vivo play an important role in cross-protective immunity. However, the live attenuated strains currently in use as vaccines are undefined, and there have been pasteurellosis outbreaks attributed to the vaccine strains (8, 13, 15, 30). Therefore, there is significant interest in producing rationally attenuated *P. multocida* mutants for use as live attenuated vaccine strains.

In gram-negative bacteria such as *Neisseria meningitidis* and *Haemophilus influenzae*, capsule is the major protective antigen and forms the basis of licensed vaccines (11). In *P. multocida* serogroup B there has been conflicting evidence on whether the capsule is a protective antigen (19, 21, 22), but the most recent work (19) indicates that the capsule is unlikely to be a protective antigen. However, no recombinant single antigens have been shown to stimulate protection against *P. multocida* serogroup B, and only limited protection in the absence of capsule has been demonstrated by passive administration of anti-LPS monoclonal antibodies (1). In contrast, rationally attenuated acapsular mutants of other species have shown promise as vaccine candidates (16, 29), suggesting that a similar approach to the development of a *Pasteurella* vaccine may be successful. Thus, the main aim of this work was to construct defined acapsular mutants of *P. multocida* and to test them for their ability to stimulate protective immunity against wild-type challenge.

We have shown previously that the *P. multocida* cexA mutant PBA875 was acapsular due to its inability to export capsule and was highly attenuated in virulence for mice (4). This acapsular strain was significantly more susceptible to macrophage uptake than wild-type bacteria and was cleared from the blood of infected mice (>99.9% of bacteria removed) in less than 4 h, while wild-type organisms multiplied rapidly. In order to determine if PBA875 could stimulate protective immunity against wild-type challenge, female 8- to 10-week-old BALB/c mice were vaccinated intraperitoneally (i.p.) with either one or two doses of live PBA875 given 14 days apart. Mice were challenged by i.p. injection of *3 × 10³* wild-type *P. multocida* M1404 (>300 50% infective dose [ID₅₀]) 1 month after the primary vaccination (Table 1). No protection was observed with immunization doses of less than *10⁶* CFU or when only a
A single immunization dose was given. However, significant protection \((P < 0.001, \text{ Fisher’s exact test})\) was observed with an immunization regime comprising two doses of either \(8 \times 10^9\) or \(8 \times 10^9\) CFU of live PBA875 (Table 1). These data indicated that live acapsular \(P.\ multocida\) could stimulate protective immunity at high immunization doses. We suggest that this dependence on dose was due to the rapid clearance of the acapsular strain from the host (4).

The acapsular strain PBA875 produced immunoreactive polysaccharide but failed to export this polysaccharide to the cell surface (4). Thus, immunity conferred by this strain could be due in part to the stimulation of antibody production by polysaccharide released from lysed cells. To investigate this possibility, we constructed a second acapsular \(P.\ multocida\) strain by inactivation of \(bcbH\), located within region 2 of the \(cap\) locus (5).

A \(P.\ multocida\) \(bcbH::\text{tet}(M)\) mutant was constructed by allelic exchange as described previously for construction of PBA875 (4). The \(\text{tet}(M)\) cassette was inserted at the unique \(EcoRI\) site within \(bcbH\), resulting in a predicted truncation of the BcbH protein at amino acid 105 of 720. The phenotype of the \(P.\ multocida\) strains was investigated by immunofluorescence (Fig. 1) and Western blotting (data not shown) using \(P.\ multocida\) serogroup B typing serum as the primary antibody.

Wild-type \(P.\ multocida\) showed strong fluorescence completely encircling the bacteria, while the mutant strain (AL18) showed only very weak fluorescence (Fig. 1). These data indicated that AL18 failed to produce immunoreactive polysaccharide.

The ID\(_{50}\) of the acapsular strain AL18 was approximately \(10^6\) CFU as determined by i.p. challenge of female BALB/c mice. Thus, like PBA875, AL18 was highly attenuated in virulence for mice. To investigate the protection conferred by vaccination with AL18 and to determine whether protection was dependent on the presence of live bacteria, female 8- to 10-week-old BALB/c mice were injected with between \(4 \times 10^5\) and \(2 \times 10^6\) CFU of either live or killed \(P.\ multocida\) M1404 or AL18. Where appropriate, bacteria were killed by incubation at 55°C for 30 min and suspensions were checked for surviving bacteria by direct plating onto nutrient agar (Difco). Mice were vaccinated either i.p. or intramuscularly (i.m.) into the upper thigh muscle at day zero, given a second dose, identical to the first 14 days later, and challenged by i.p. injection of 120 CFU of wild-type \(P.\ multocida\) M1404 (\(>12\) ID\(_{50}\) [4]) 15 days after the second vaccination. Mice were observed for signs of disease and were killed by cervical dislocation when deemed moribund. Female 8- to 10-week-old BALB/c mice usually succumbed within 36 h, and mice which survived for at least 1 week after challenge were deemed immune. There was no significant difference observed in time to death for sensitive mice.

#### TABLE 1. Protection conferred by immunization with live \(P.\ multocida\) capsule-deficient mutant

<table>
<thead>
<tr>
<th>Immunization dose (CFU)</th>
<th>Booster dose</th>
<th>% Survival (no. of animals in group)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None (BHIB)</td>
<td>No</td>
<td>0 (11)</td>
</tr>
<tr>
<td>(8 \times 10^9)</td>
<td>No</td>
<td>0 (10)</td>
</tr>
<tr>
<td>(8 \times 10^9)</td>
<td>Yes</td>
<td>0 (10)</td>
</tr>
<tr>
<td>(8 \times 10^9)</td>
<td>Yes</td>
<td>0 (6)</td>
</tr>
<tr>
<td>(8 \times 10^7)</td>
<td>Yes</td>
<td>77 (9)(^a)</td>
</tr>
<tr>
<td>(8 \times 10^7)</td>
<td>No</td>
<td>0 (10)</td>
</tr>
<tr>
<td>(8 \times 10^6)</td>
<td>Yes</td>
<td>88 (8)(^a)</td>
</tr>
</tbody>
</table>

\(^a\) Mice were immunized with live acapsular \(P.\ multocida\) (PBA875) cecA::\text{tet}(M) mutant in 0.1 ml of brain heart infusion broth (BHIB).

\(^b\) Mice were challenged with \(3 \times 10^9\) CFU of wild type \(P.\ multocida\) M1404, observed for signs of disease, and killed by cervical dislocation when deemed moribund, in accordance with animal ethics requirements. Significant protection compared to nonimmunized controls \((P < 0.001, \text{ Fisher’s exact test})\). Significance was determined using identical integration times. 

Figure 1: Phenotypic characterization of \(P.\ multocida\) capsule expression. Digital photomicrographs of methanol-fixed \(P.\ multocida\) 1404 (wild-type) (A) and AL18 acapsular mutant (B) visualized by immunofluorescence, with \(P.\ multocida\) serogroup B typing antiserum as the primary antibody and fluorescein isothiocyanate-labeled anti-rabbit immunoglobulin as the secondary antibody. Both charge-coupled device images were acquired using identical integration times.
TABLE 2. Protection conferred by immunization with live or killed *P. multocida* strains

<table>
<thead>
<tr>
<th>Strain**</th>
<th>Immunization route</th>
<th>% Survival (no. of animals in group)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>None (BHIB)</td>
<td>i.p.</td>
<td>0 (5)</td>
</tr>
<tr>
<td>None (BHIB)</td>
<td>i.m.</td>
<td>0 (5)</td>
</tr>
<tr>
<td>AL18 (live)</td>
<td>i.p.</td>
<td>90 (10)‡</td>
</tr>
<tr>
<td>AL18 (live)</td>
<td>i.m.</td>
<td>50 (10)‡</td>
</tr>
<tr>
<td>AL18 (killed)</td>
<td>i.p.</td>
<td>0 (5)</td>
</tr>
<tr>
<td>AL18 (killed)</td>
<td>i.m.</td>
<td>40 (5)</td>
</tr>
<tr>
<td>M1404 (killed)</td>
<td>i.p.</td>
<td>40 (5)</td>
</tr>
<tr>
<td>M1404 (killed)</td>
<td>i.m.</td>
<td>0 (5)</td>
</tr>
</tbody>
</table>

* Mice were immunized with either live or killed *P. multocida* AL18 (acapsular mutant) or M1404 (wild type) in 0.05 ml of brain heart infusion broth (BHIB). ** Mice were challenged with 120 CFU of wild-type *P. multocida* M1404, observed for signs of disease, and killed by cervical dislocation when deemed moribund, in accordance with animal ethics requirements. Sensitive mice usually succumbed within 36 h, and mice which survived for at least 1 week after challenge were deemed immune. There was no significant difference observed in time to death for sensitive mice. ‡ Significant protection compared to nonimmunized controls (P < 0.05; Fisher’s exact test).

We thank Vicki Vallance and Ian McPherson for excellent technical assistance and Harry Sakellariou and Jing Chung for critical reading of the manuscript. We thank the late Rick Rimler for providing the type B capsular antiserum.

This work was funded in part by a grant from the Australian Research Council, Canberra, Australia.

REFERENCES

22. Penn, C. W., and L. K. Nagy. 1976. Isolation of a protective, non-toxic...

Editor: W. A. Petri, Jr.